Anti-TIGIT therapies for solid tumors: a systematic review

Programmed death-ligand 1[PD-(L)1], cytotoxic T-lymphocyte associated protein 4 (CTLA-4), and lymphocyte-activation gene 3 (LAG-3) inhibitors are recent breakthroughs in cancer treatment, however not all patients benefit from it. Thus new therapies are under investigation, such as anti-TIGIT [anti-T...

Descripción completa

Detalles Bibliográficos
Autores principales: Rousseau, A., Parisi, C., Barlesi, F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10030909/
https://www.ncbi.nlm.nih.gov/pubmed/36933320
http://dx.doi.org/10.1016/j.esmoop.2023.101184

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10030909/
https://www.ncbi.nlm.nih.gov/pubmed/36933320
http://dx.doi.org/10.1016/j.esmoop.2023.101184

Ejemplares similares